Page 3 - Between Sept News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related interstitial lung disease was more common with patients receiving trastuzumab deruxtecan. Evidence Rating Level: 1 (Excellent) Study Rundown: A large proportion of breast cancers are characterized by overexpression of HER2 receptors. While first-line therapy for

1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion of adverse events in both groups was comparable between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute myeloid leukemia (AML) is an aggressive form of blood cancer with poor clinical outcomes. In patients with

BEIJING, Feb. 20 (Xinhua) -- Japanese automaker Toyota started to recall Lexus imported cars from the Chinese market over safety concerns, China top quality wat

By Ty McCormick In 2012, the world witnessed an unusual number of high profile elections. Between the US battle royale, Vladimir Putin’s return to...

Decline of COVID-19 cases in Brevard County stagnates. Meanwhile, the vaccination rate continues to slowly creep up.